PAM Pathway
Overactivation of the PAM (PI3K/AKT/mTOR) pathway plays a key role in the progression of a wide variety of human cancers.
REVTORPYK™ (gedatolisib) is FDA-approved as a 2nd-line treatment for HR+/HER2-PIK3CA wild-type advanced breast cancer.
Our Pipeline
We are evaluating gedatolisib across a range of solid tumors to improve patient outcomes.
Clinical Trials
We have multiple ongoing clinical trials for gedatolisib as a potential treatment for breast and prostate cancer.
Recent News
November 3, 2026
Celcuity To Participate in Upcoming Investor Conferences
October 29, 2026
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
October 24, 2026
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026